Compare RVSN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | MBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.1M |
| IPO Year | 2018 | 2016 |
| Metric | RVSN | MBRX |
|---|---|---|
| Price | $3.54 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 16.5K | ★ 1.1M |
| Earning Date | 03-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.16 |
| 52 Week High | $9.39 | $7.98 |
| Indicator | RVSN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 39.29 |
| Support Level | $3.26 | $0.16 |
| Resistance Level | $5.09 | $0.67 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 31.37 | 17.47 |
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.